Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose ...
NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...
A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using ...
Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026--Phase 1a clinical data for CTX310® ...
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive ...
The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA ...
It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results